



Express Mail No.: EV475141657US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Santini, Jr. et al.  
Serial No.: 10/768,315  
Filed: January 30, 2004  
For: STENT FOR CONTROLLED RELEASE OF DRUG

Confirmation No.: 6323  
Art Unit: 3738  
Examiner: Phan, Hieu  
Attorney: 10177-291-999  
Docket No.: CAM: 008563-999287

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

The fee for processing the attached Terminal Disclaimer is believed to be \$110.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Date: September 20, 2005

54,390

  
Brent P. Ray  
For: Gidon D. Stern (Reg. No. 27,469)  
JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

(Reg. No.)

09/26/2005 MAHMED1 00000055 503013 10768315

02 FC:1814 130.00 DA

NYJD: 1588314.1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Santini, Jr. et al. Confirmation No.: 6323  
Serial No.: 10/768,315 Art Unit: 3738  
Filed: January 30, 2004 Examiner: Phan, Hieu  
For: STENT FOR CONTROLLED Attorney: 10177-291-999  
RELEASE OF DRUG Docket No.: CAM: 008563-999287

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Your Petitioner, Scott T. Bluni, Esq. represents that (s)he holds the position of **Assistant Secretary of Boston Scientific Scimed, Inc.**, the assignee of the entire 100% right, title and interest in and to the above identified application by virtue of an assignment which was recorded on **July 19, 2005** at reel **016274** frame **0728**.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent No. 6,656,162 which issued on December 2, 2003 and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,656,162.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,565,162 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of **Boston Scientific Scimed, Inc.**

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code

and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 1<sup>st</sup> day of Sept, 2005.

**Boston Scientific Scimed, Inc.**

By: 

Name: Scott T. Bluni, Esq.  
Position: Assistant Secretary